PL2958913T3 - Agoniści receptora sfingozyno-1-fosforanowego, sposoby ich przygotowania i zawierające je jako środek aktywny farmaceutyczne kompozycje - Google Patents
Agoniści receptora sfingozyno-1-fosforanowego, sposoby ich przygotowania i zawierające je jako środek aktywny farmaceutyczne kompozycjeInfo
- Publication number
- PL2958913T3 PL2958913T3 PL14753476T PL14753476T PL2958913T3 PL 2958913 T3 PL2958913 T3 PL 2958913T3 PL 14753476 T PL14753476 T PL 14753476T PL 14753476 T PL14753476 T PL 14753476T PL 2958913 T3 PL2958913 T3 PL 2958913T3
- Authority
- PL
- Poland
- Prior art keywords
- same
- sphingosine
- preparing
- methods
- pharmaceutical compositions
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130018293 | 2013-02-20 | ||
| PCT/KR2014/001336 WO2014129796A1 (en) | 2013-02-20 | 2014-02-19 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| EP14753476.2A EP2958913B1 (en) | 2013-02-20 | 2014-02-19 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2958913T3 true PL2958913T3 (pl) | 2019-03-29 |
Family
ID=51391525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14753476T PL2958913T3 (pl) | 2013-02-20 | 2014-02-19 | Agoniści receptora sfingozyno-1-fosforanowego, sposoby ich przygotowania i zawierające je jako środek aktywny farmaceutyczne kompozycje |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9540362B2 (pl) |
| EP (1) | EP2958913B1 (pl) |
| JP (1) | JP6294359B2 (pl) |
| KR (1) | KR101939657B1 (pl) |
| CN (1) | CN105051037B (pl) |
| AU (1) | AU2014219575B2 (pl) |
| BR (1) | BR112015019794B1 (pl) |
| DK (1) | DK2958913T3 (pl) |
| ES (1) | ES2698359T3 (pl) |
| HU (1) | HUE039931T2 (pl) |
| MX (1) | MX370032B (pl) |
| PL (1) | PL2958913T3 (pl) |
| PT (1) | PT2958913T (pl) |
| RU (1) | RU2654483C2 (pl) |
| SI (1) | SI2958913T1 (pl) |
| TW (1) | TWI582073B (pl) |
| WO (1) | WO2014129796A1 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| KR102644587B1 (ko) * | 2015-12-24 | 2024-03-07 | (주)아모레퍼시픽 | 유사 세라마이드 화합물 및 그 제조방법 |
| US10730830B2 (en) | 2016-01-29 | 2020-08-04 | Ono Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
| WO2018014862A1 (zh) * | 2016-07-22 | 2018-01-25 | 南京明德新药研发股份有限公司 | S1p1激动剂及其应用 |
| WO2018162607A1 (en) * | 2017-03-07 | 2018-09-13 | F. Hoffmann-La Roche Ag | Oxadiazole transient receptor potential channel inhibitors |
| CN107382965A (zh) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法 |
| KR101891051B1 (ko) * | 2018-01-29 | 2018-08-31 | 주식회사 세종바이오메드 | 스핑고신-1-포스페이트 유사체 및 이의 합성 방법 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| KR20210123321A (ko) * | 2019-01-11 | 2021-10-13 | 내기스 파마슈티컬스 인코포레이티드 | 류코트리엔 합성 억제제 |
| CN110240537B (zh) * | 2019-05-22 | 2022-06-21 | 成都阿奇生物医药科技有限公司 | 一种茚氧乙酸类化合物及其制备方法和用途 |
| BR112022010761A2 (pt) | 2019-12-03 | 2022-08-23 | Lg Chemical Ltd | Agonista do receptor de esfingosina-1-fosfato, método de preparação do mesmo e composição farmacêutica contendo o mesmo como ingrediente ativo |
| KR20210073998A (ko) | 2019-12-11 | 2021-06-21 | 주식회사 엘지화학 | 다발성 경화증 예방 또는 치료용 약제학적 조성물 |
| CN116437921A (zh) | 2020-09-28 | 2023-07-14 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的用途 |
| TW202220651A (zh) * | 2020-09-28 | 2022-06-01 | 南韓商Ｌｇ化學股份有限公司 | 神經鞘胺醇－１－磷酸受體促效劑的用途 |
| WO2022080813A1 (ko) | 2020-10-13 | 2022-04-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
| WO2022080812A1 (ko) * | 2020-10-13 | 2022-04-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
| TW202302538A (zh) * | 2021-04-14 | 2023-01-16 | 南韓商Ｌｇ化學股份有限公司 | 製備用於合成鞘胺醇—１—磷酸酯受體促效劑之中間體的方法 |
| EP4324827A4 (en) * | 2021-04-14 | 2024-08-21 | Lg Chemical Ltd | PHARMACEUTICALLY ACCEPTABLE SALT OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST AND CRYSTALLINE FORM THEREOF |
| CN117120426A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的结晶形式 |
| JP2024514184A (ja) * | 2021-04-14 | 2024-03-28 | エルジー・ケム・リミテッド | 粒度が制御されたスフィンゴシン－１－リン酸受容体アゴニストを含む医薬組成物 |
| WO2022220599A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| KR20220142388A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 신규한 제조방법 |
| KR20220142376A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물 |
| EP4306514A4 (en) * | 2021-04-14 | 2024-09-11 | Lg Chemical Ltd | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR THE SYNTHESIS OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST |
| CN117120038A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 包含鞘氨醇-1-磷酸受体激动剂的固体制剂的制备方法 |
| JP2024515077A (ja) * | 2021-04-14 | 2024-04-04 | エルジー・ケム・リミテッド | スフィンゴシン－１－リン酸受容体アゴニストの結晶形 |
| CN117120425A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的晶体形式 |
| WO2022220608A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
| WO2022220596A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 습식과립법에 의한 스핑고신-1-인산 수용체 효능제를 포함하는 경구용 고형 제제의 제조 방법 |
| TWI823341B (zh) * | 2021-04-14 | 2023-11-21 | 南韓商Ｌｇ化學股份有限公司 | 製備鞘胺醇－１－磷酸酯受體促效劑的新穎方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011255A1 (fr) * | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Regulateurs du recepteur active par les agents de proliferation des peroxysomes |
| AU2003261935A1 (en) | 2002-09-06 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| JP2006516254A (ja) | 2003-01-06 | 2006-06-29 | イーライ・リリー・アンド・カンパニー | Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体 |
| EP1631542A1 (en) | 2003-04-10 | 2006-03-08 | Amgen, Inc. | Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
| US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| EP2371811B1 (en) | 2004-12-13 | 2014-10-08 | Ono Pharmaceutical Co., Ltd. | Azetidinecarboxylic acid derivative and medicinal use thereof |
| CA2595514C (en) | 2005-01-26 | 2012-06-12 | Schering Corporation | Kinase inhibitors |
| US20090082349A1 (en) | 2006-03-02 | 2009-03-26 | Dashyant Dhanak | Thiazolones for use as pi3 kinase inhibitors |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| JP2009269819A (ja) * | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| AU2007323540A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| US20110207704A1 (en) * | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| JP4792126B2 (ja) | 2007-08-01 | 2011-10-12 | ファイザー・インク | ピラゾール化合物およびＲａｆ阻害剤としてのその使用 |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PT2913326T (pt) | 2008-05-14 | 2020-08-24 | Scripps Research Inst | Novos moduladores de recetores de fosfato de esfingosina |
| US8153103B2 (en) | 2008-07-01 | 2012-04-10 | Board Of Regents, The University Of Texas System | Conjugates of photo-activatable dyes |
| WO2010042998A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
| KR20110100624A (ko) | 2008-12-18 | 2011-09-14 | 메르크 세로노 에스. 에이. | 다발성 경화증의 치료에 유용한 옥사디아졸 융합된 헤테로사이클릭 유도체 |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| US20100174539A1 (en) | 2009-01-06 | 2010-07-08 | Qualcomm Incorporated | Method and apparatus for vector quantization codebook search |
| KR20100092909A (ko) | 2009-02-13 | 2010-08-23 | 주식회사 엘지생명과학 | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
| EP2241558A1 (en) | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| KR101892987B1 (ko) | 2009-04-22 | 2018-08-30 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| EP2445891A4 (en) | 2009-06-26 | 2012-11-14 | Glaxo Group Ltd | 5-CHAIN HETEROARYL DERIVATIVES AS SPHINOSINE-1-PHOSPHATE RECEPTOR AGONISTS |
| MX2012005562A (es) | 2009-11-13 | 2012-10-05 | Receptos Inc | Moduladores del receptor de esfingosina 1 fosfato y metodos de sintesis quiral. |
| NZ599914A (en) | 2009-11-13 | 2014-08-29 | Receptos Inc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| JP5939158B2 (ja) * | 2009-11-24 | 2016-06-22 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 治療的有用性を有する受容体調節物質としての新規化合物 |
| EP2390252A1 (en) * | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| KR20130133216A (ko) * | 2010-11-24 | 2013-12-06 | 알러간, 인코포레이티드 | S1p 수용체의 신규한 인돌 조절제 |
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
-
2014
- 2014-02-19 DK DK14753476.2T patent/DK2958913T3/en active
- 2014-02-19 MX MX2015009986A patent/MX370032B/es active IP Right Grant
- 2014-02-19 TW TW103105447A patent/TWI582073B/zh active
- 2014-02-19 CN CN201480009397.9A patent/CN105051037B/zh active Active
- 2014-02-19 PT PT14753476T patent/PT2958913T/pt unknown
- 2014-02-19 PL PL14753476T patent/PL2958913T3/pl unknown
- 2014-02-19 HU HUE14753476A patent/HUE039931T2/hu unknown
- 2014-02-19 US US14/764,116 patent/US9540362B2/en active Active
- 2014-02-19 KR KR1020140019113A patent/KR101939657B1/ko active IP Right Grant
- 2014-02-19 AU AU2014219575A patent/AU2014219575B2/en active Active
- 2014-02-19 JP JP2015559180A patent/JP6294359B2/ja active Active
- 2014-02-19 SI SI201430907T patent/SI2958913T1/sl unknown
- 2014-02-19 BR BR112015019794-9A patent/BR112015019794B1/pt active IP Right Grant
- 2014-02-19 WO PCT/KR2014/001336 patent/WO2014129796A1/en active Application Filing
- 2014-02-19 RU RU2015139594A patent/RU2654483C2/ru active
- 2014-02-19 ES ES14753476T patent/ES2698359T3/es active Active
- 2014-02-19 EP EP14753476.2A patent/EP2958913B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016513126A (ja) | 2016-05-12 |
| SI2958913T1 (sl) | 2018-12-31 |
| WO2014129796A1 (en) | 2014-08-28 |
| PT2958913T (pt) | 2018-12-03 |
| RU2015139594A (ru) | 2017-03-27 |
| HUE039931T2 (hu) | 2019-02-28 |
| BR112015019794B1 (pt) | 2022-09-13 |
| AU2014219575A1 (en) | 2015-08-20 |
| CN105051037A (zh) | 2015-11-11 |
| MX370032B (es) | 2019-11-28 |
| RU2654483C2 (ru) | 2018-05-21 |
| KR20140104376A (ko) | 2014-08-28 |
| TW201444794A (zh) | 2014-12-01 |
| TWI582073B (zh) | 2017-05-11 |
| EP2958913A1 (en) | 2015-12-30 |
| MX2015009986A (es) | 2015-10-05 |
| ES2698359T3 (es) | 2019-02-04 |
| EP2958913A4 (en) | 2016-10-05 |
| AU2014219575B2 (en) | 2017-07-06 |
| DK2958913T3 (en) | 2018-11-05 |
| US9540362B2 (en) | 2017-01-10 |
| KR101939657B1 (ko) | 2019-01-17 |
| JP6294359B2 (ja) | 2018-03-14 |
| BR112015019794A8 (pt) | 2018-08-14 |
| BR112015019794A2 (pt) | 2017-07-18 |
| EP2958913B1 (en) | 2018-10-03 |
| US20150376173A1 (en) | 2015-12-31 |
| CN105051037B (zh) | 2018-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2958913A4 (en) | SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFOR AS ACTIVE AGENT | |
| HRP20190164T1 (hr) | Paraziticidni oralni veterinarski sastavi koji obuhvaćaju djelatne tvari sa sustavnim djelovanjem, i načini njihove primjene | |
| EP2917180A4 (en) | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE | |
| EP3065742A4 (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| HK1215567A1 (zh) | 五元併六元雜環化合物、其製備方法、藥物組合物和應用 | |
| HK1221654A1 (zh) | 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統 | |
| EP3012256A4 (en) | HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF | |
| EP3054933A4 (en) | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same | |
| PL2961822T3 (pl) | Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie | |
| EP2941418A4 (en) | N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| IL243223B (en) | History of imidazole, their preparation and pharmaceutical preparations containing them | |
| EP2978421A4 (en) | STABLE NANOCOMPOSITION COMPRISING DOCATEXEL, PROCESS FOR PREPARATION THEREOF, USE THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| HUE044798T2 (hu) | Agomelatin és p-toluol-szulfonsav kokristályai, eljárás elõállításukra, és ezeket tartalmazó gyógyszerészeti készítmények | |
| UA88242U (ru) | Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия |